Helicobacter Pylori Infection Clinical Trial
Official title:
Prospective Analysis of the Eradication Percentage of Helicobacter Pylori, to Evaluate the Effect of Standardized Eradication Schemes and Active Communication With the General Practitioner and Patient.
Patients who test Helicobacter pylori positive, are treated with antibiotics. However, due to
a number of factors (such as unknown treatment compliance, no standardized follow-up, ...), a
relative low eradication-percentage was reported.
Therefore, the investigators want to measure the anticipated improvement in
eradication-percentage due to the standardized treatment schedules (1st line, 2nd line and
further) and the optimized communication with the general practitioner and patients.
Patients who test Helicobacter pylori positive, are treated with antibiotics. However, due to
a number of factors (such as unknown treatment compliance, no standardized follow-up, ...), a
relative low eradication percentage was reported. Therefore, the investigators want to
measure the anticipated improvement in eradication percentage due to the standardized
treatment schemes (1st line, 2nd line and further) and the optimized communication with the
general practitioner and patients.
If a patient is eligible (Helicobacter pylori positive) :
1. The standardized eradication scheme in 1st line is:
sequential therapy being the first 5 days (PPI 2x40mg/d + amoxicilline 2x1g/d), followed
by 5 days (PPI 2x40mg/d + clarithromycin 2x500mg/d + flagyl 2x500mg/d)
2. A standardized letter is sent to the general practitioner, mentioning the eradication
scheme, and the need to test for eradication success after 8 weeks. A copy of this
letter is being sent to the patient. An information folder about Helicobacter pylori
infection with instructions on what is expected from the patient, is sent to the
patient.
3. After 8 weeks, a control helicobacter pylori breath test (An ureum breath test is a type
of test performed on air generated from the act of exhalation ; this test is specific to
detect Helicobacter pylori) is performed, and a questionnaire is filled in by the
patient.
4. If the ureum breath test is positive, a 2nd line treatment is started = tryplera
schedule for 10 days (4x3 co/dag + PPI 2x40mg/d) (1 co tryplera contains 140mg
bismuthsubcitrate, 125mg metronidazole, 125mg tetracycline hydrochloride)
5. A standardized letter is sent to the general practitioner, mentioning the 2nd line
eradication scheme, and the need to test for eradication success after 8 weeks. A copy
of this letter is being sent to the patient.
6. After 8 weeks, a control helicobacter pylori breath test is performed, and a
questionnaire is filled in by the patient.
7. If the breath test is positive, a 3rd line treatment is started, based on the results of
an antibiogram.
8. A standardized letter is sent to the general practitioner, mentioning the 3rd line
eradication schedule, and the need to test for eradication success after 8 weeks. A copy
of this letter is being sent to the patient.
9. After 8 weeks, a control helicobacter pylori breath test is performed, and a
questionnaire is filled in by the patient.
Overall time-frame : a maximum of 100 helicobacter-positive patients will be recruited over a
period of 1 year. Included patients are followed up for 30 weeks maximally.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05061732 -
Helicobacter Pylori Eradication and Follow-up
|
Phase 4 | |
| Completed |
NCT03779074 -
Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies
|
Phase 3 | |
| Completed |
NCT06076681 -
A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05329636 -
Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05065138 -
Comparison of Helicobacter Pylori Eradication Effect Before and After Training of Gastroenterologists
|
N/A | |
| Completed |
NCT05049902 -
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
|
Phase 4 | |
| Not yet recruiting |
NCT06200779 -
Tailored vs. Empirical Helicobacter Pylori Infection Treatment
|
Phase 4 | |
| Not yet recruiting |
NCT06037122 -
Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication
|
||
| Completed |
NCT04617613 -
Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait
|
Phase 4 | |
| Withdrawn |
NCT02552641 -
Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole
|
Phase 4 | |
| Completed |
NCT02557932 -
Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication
|
Phase 3 | |
| Recruiting |
NCT02249546 -
Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection
|
Phase 4 | |
| Completed |
NCT01933659 -
Anti-H. Pylori Effect of Deep See Water
|
Phase 3 | |
| Unknown status |
NCT01464060 -
14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication
|
Phase 4 | |
| Completed |
NCT00841490 -
Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults
|
N/A | |
| Recruiting |
NCT05728424 -
One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL
|
Phase 3 | |
| Recruiting |
NCT05549115 -
Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection
|
N/A | |
| Recruiting |
NCT05997433 -
Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302)
|
N/A | |
| Completed |
NCT04708405 -
The Relationship Between Helicobacter Pylori Infection and Inflammatory Bowel Diseases: A Real-life Observation
|
||
| Completed |
NCT06282484 -
A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions
|